You are here: Industry Insights > Bristol-Myers Squibb

News List

Bristol-Myers' Lung Cancer Opdivo Trial Stopped Early for Superior Overall Survival biospace
December 04, 2017
Bristol-Myers Squibb has its eyes set on carving out a strong position in the lucrative Chinese lung cancer market.
BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness worldpharmanews
November 13, 2017
Bristol-Myers Squibb and Pfizer plan to release actual data on the results of direct oral anticoagulation in patients with non-valvular atrial fibrillation Using the U.S. Medicare Database
FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high worldpharmanews
October 18, 2017
FDA has accepted for priority review its supplemental Biologics License Application for Opdivo to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
Bristol-Myers Squibb Appoints Senior Vice President, Global Head of Translational Medicine pharmaceufical-technology
October 10, 2017
Bristol-Myers Squibb has appointed Saurabh Saha, M.D., Ph.D. as senior vice president and global head of translational medicine in the company’s R&D organization.
AbbVie, Bristol-Myers Squibb Announce Clinical Research Collaboration americanpharmaceuticacreview
September 25, 2017
AbbVie is the sponsor conducting the trial. Specific terms of the agreement were not disclosed.
AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic r worldpharmanews
September 25, 2017
clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
Bristol-Myers Squibb collaborates with ENHANZE technology biospectrumasia
September 18, 2017
Under the agreement, Halozyme to receive $105 million upfront payment, plus future milestones and royalties
Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE techn worldpharmanews
September 15, 2017
Bristol-Myers Squibb Company announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology.
Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics worldpharmanews
September 08, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics.
Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Sta worldpharmanews
September 07, 2017
The first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride

Previous page 1 2 3 4 5 6 7 8 9 10 Next page